NeuroSearch AS (NEUR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations.The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats.
The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including: - Business description – A detailed description of the company’s operations and business divisions. - Corporate strategy – Analyst’s summarization of the company’s business strategy. - SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats. - Company history – Progression of key events associated with the company. - Major products and services – A list of major products, services and brands of the company. - Key competitors – A list of key competitors to the company. - Key employees – A list of the key executives of the company. - Executive biographies – A brief summary of the executives’ employment history. - Key operational heads – A list of personnel heading key departments/functions. - Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company. - Key manufacturing facilities – A list of key manufacturing facilities of the company. - Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history. - Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights NeuroSearch AS (NeuroSearch) focuses on the development of novel pharmaceutical agents for the treatment of various disorders of central nervous system (CNS) through license agreements with other life science companies.The company divested all rights of Huntexil for the treatment of patients with Huntington’s disease to Teva Pharmaceuticals.
It also sold all the preclinical and clinical assets, and further development of NS2330 (tesofensine) and NS2359 as well as of any potential drugs based on NS2330 or NS2359 to Saniona A/S and Saniona AB (Saniona).NeuroSearch is entitled to receive a one-time cash payment from Saniona and milestone payments from Teva.
NeuroSearch is headquartered in Hallerup, Denmark.
NeuroSearch AS Key Recent Developments Aug 30,2018: NeuroSearch – H1 report 2018 Dec 05,2017: Update on NeuroSearch’s business status and future Aug 31,2017: NeuroSearch – H1 report 2017 Feb 24,2017: NeuroSearch releasing Annual Report 2016
Key benefits of buying this profile include: You get detailed information about the company and its operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company. - The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably. - Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance. - Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research. - Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Our reports have been used by over 10K customers, including:
Bone Metastasis - Pipeline Review, H2 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Bone Metastasis - Pipeline Review, H2 2018, provides an overview of the Bone Metastasis (Oncology) pipeline landscape. Bone metastasis occurs when cancer cells...
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 18.104.22.168) - Pipeline Review, H2 2018 Summary Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 22.214.171.124) pipeline Target constitutes close to 26 molecules. The latest report Tyrosine Protein Kinase...
Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 126.96.36.199) - Pipeline Review, H2 2018 Summary Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 188.8.131.52) - Phenylalanine 4 hydroxylase or Phenylalanine hydroxylase (PAH) is an enzyme that catalyzes the hydroxylation of the...
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 184.108.40.206) - Pipeline Review, H2 2018 Summary Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 220.127.116.11) - Cyclin-dependent kinase 4 is an enzyme encoded by the CDK4 gene. Ser/Thr-kinase...
Global Pharmaceutical Partnering Terms and Agreements 2012 to 2018 report provides a detailed understanding and analysis of how and why companies enter Pharmaceutical partnering deals. This report provides details of the latest Pharmaceutical agreements announced in the life sciences since 2012. The report takes...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.